Therapeutic Efficacy Model To Chemotherapy In Patients With Advanced Gastric Cancer Treated With Taxane-based Regimens

[Objective]Taxane is active against gastric cancer and taxane-based combined chemotherapy is effective in the treatment of advanced gastric cancer (AGC). The purpose of this study was to investigate the factors about influence of therapeutic efficacy to 72 patients with AGC treated with taxane-based regimens, establish a chemotherapy efficacy model, provide scientific basis to clinical treatment and direct individual and standardized treatment.[Methods]Seventy-two cases of AGC treated with taxane-based regimens from 2003 to 2008 were enrolled in this study. Nineteen clinical factors were analyzed including gender, age, Karnofsky performance status (KPS) before chemotherapy, pathological types, degree of histologic differentiation, metastatic sites, chemotherapy was done or not , primary treatment or retreatment, anemia or not, cycle of chemotherapy, toxicities of chemotherapy, carcinoembryonicantigen (CEA), carbohydrate antigen 125 (CA125), carbohydrate antigen 199 (CA199), alpha fetoprotein (AFP). The data was analyzed by using STATA8. Univariate and multivariate analysis were done through Logistic regression model, then establish a chemotherapy efficacy model on the basis of regression coefficient.[Results]The results of univariate analysis of 72 cases showed that the 5 factors, metastatic sites, chemotherapy was done or not , cycle of chemotherapy, anemia and white blood count (WBC), were related to the efficacy (P<0.05). Thirteen factors including gender, age, KPS, pathological types, degree of histologic differentiation, metastatic sites, chemotherapy was done or not, primary treatment or retreatment, cycle of chemotherapy, CEA, CA125, CA199, AFP were done through Logistic multivariate analysis. The results indicated that pathological types, metastatic sites, chemotherapy was done or not and cycle of chemotherapy were independent influence factors. A chemotherapy efficacy model was established by the 4 factors:b0 is a constant, X1-X4 represent pathological types, metastatic sites, chemotherapy was done or not and cycle of chemotherapy. b1-b4 are the regression coefficients of factors. In our study, b0+b1X1+b2X2+…+biXi means -7.008161 - 1.433467 pathological types + 1.424615 metastatic sites + 4.268529 chemotherapy was done or not + 1.712759 cycle of chemotherapy.[Conclusions]1) In all the factors of 72 AGC cases, pathological types, metastatic sites, chemotherapy was done or not and cycle of chemotherapy were independent influence factors. The taxane-based regimens chemotherapy efficacy model was b0+b1X1+b2X2+…+biXi means: -7.008161 - 1.433467 pathological types + 1.424615 metastatic sites + 4.268529 chemotherapy was done or not + 1.712759 cycle of chemotherapy.2) The chemotherapy efficacy model, theoretically, could predict the chemotherapy efficacy in patients with AGC treated with taxane-based regimens. It is guidance in the clinical treatment to improve the survival rate of gastric cancer.